Previous Close | 17.5 |
1-Year Change | -26.5% |
6-Months Change | -31.16% |
3-Months Change | -21.91% |
Moving Avg (50d) | 19.069 |
Moving Avg (200d) | 23.537 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 1.56B |
Beta (3-Years) | 2.04 |
Revenue Growth (ttm) | -55.51% |
Net Profit Margin (ttm) | -4867.77% |
Return On Assets (ttm) | -37.19% |
EPS (ttm) | -5.33 |
PE Ratio (ttm) | -3.28 |
Dividend Yield | % |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |
Intellia Therapeutics is a clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company’s in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues.... Wikipedia